

Human Interferon-beta 1b protein (Recombinant) (STJP000324)

STJP000324

GENERAL INFORMATION


Product Type	Proteins
Short Description	Recombinant-Human Interferon-beta 1b-protein was developed from cho cells. For use in research applications.
Host/Source	CHO cells

PRODUCT PROPERTIES


Concentration	
Formulation	Lyophilised from 0.2 Mu m filtered solution containing mM NaOAc pH.5.
Purification	
Dilution Range	>95%, as determined by SDS-PAGE and HPLC NA
Storage	Can be stored in working aliquots at°C°C C for one month, or at-20°C C for six months, with a carrier protein without detectable
Instruction	loss of activity. Avoid repeated freeze/thaw cycles. NA

TARGET INFORMATION


Gene ID	3456
Gene Symbol	IFNB1
Uniprot ID	IFNB_HUMAN
Immunogen Sequence	




Following the initial culture period, islets were cultured for an additional 624h in CMRL 1066 containing antibiotics, 2 mM glutamine and one of the following supplements: 0.5 mM sodium pyalinate solubilized in 0.5% (weight/volume) fatty acid and cholesterol, 100 U/ml recombinant human Interleukin-1beta (IL-1 α) (50 units/ml) and recombinant human Interferon-beta (IFN- β) (100 ng/ml) and recombinant human Interleukin-1beta (IL-1 α) (50 units/ml) and Interferon-gamma (IFN-Gamma) (50 Mu l) (100 ng/ml) : 100 mM hydrazine, 1% Triton X-100, 1 mMol/l phenylmethylsulfonyl fluoride (PMSF) and 10 Mu g/ml aprotinin) as modified from the reports of Kim et al. and Moon et al. [



Interferon gamma (IFN-Gamma) 50 Mu l (100 ng/ml) was added to each dish in the experimental studies. The cytoplasmic and nuclear extracts were washed with ice-cold PBS and lysed in a 0.5% Triton X-100, 1 mMol/l phenylmethylsulfonyl fluoride (PMSF) and 10 Mu g/ml aprotinin) as modified from the reports of Kim et al. and Moon et al. [



E) Recombinant Type III Interferons in the absence of CM at the same concentrations as found in the CM (IL-28A/IFN Lambda 2: 1000 pg/ml; IL-28B/IFN Lambda 3: 10 pg/ml; IL-29/IFN Lambda 1: 500 pg/ml) were added to JFH-1 infected HuH7.5.1 cells.



Venous blood was collected prior to chemotherapy or at least one month following chemotherapy. For the offspring (HLA haploididentical donors), the routine blood tests, and liver and kidney function tests were performed. Serological markers A virus-IgM, hepatitis B surface antigen antibody, hepatitis B e-antigen hepatitis B core-hepatitis C virus (HCV)-IgG, IgM, Sypheitis and hepatitis C virus were measured. For the first 18 days of the study (2 atmosphere). On the day of culture, 1000 U/ml human recombinant Interferon-Gamma, 500 U/ml recombinant human Interferon- α (rhIFN- α 1 Alpha) and 1000 U/ml rhIL-2 (Omega Biotech International) were added. For days 19-36, 1000 U/ml rhIL-2 was added and the cells were transferred into a GT-610 culture bag. Cell viability was observed every other day and cells were stained with 0.4% trypan blue and viable cells were counted. Following 18 days of culture, cells were infused once daily (>1A 109 cells; viability rate, >95%). A cycle of treatment: